Roda Giulia, Caponi Alessandra, Sartini Alessandro, Cevenini Monica, Colliva Carolina, Roda Aldo
Gastroenterology Unit, S. Orsola-Malpighi Hospital (Giulia Roda, Alessandra Caponi, Alessandro Sartini).
Department of Clinical Medicine, University of Bologna, S. Orsola Hospital (Monica Cevenini).
Ann Gastroenterol. 2012;25(4):303-308.
Ulcerative colitis and Crohn's disease are relapsing and remitting chronic disorders. So far, endoscopy is the gold standard for their diagnosis, but less invasive diagnostic biomarkers are needed. Many authors have developed techniques to individuate biomarkers such as genetic testing factor or proteins in biological samples such as serum, plasma, and cellular subpopulations. A protein fingerprint pattern, patient-unique, specific for the diagnosis of inflammatory bowel disease (IBD) and potentially able to predict the future patterns of disease and to help in diagnosis, treatment, and prognosis is of increasing interest among researchers. Nowadays, a proteomic approach may be used in the identification of major alterations of proteins in IBD, but there is still a lack in the identification of a panel of biomarkers among a significant number of patients in large clinical trials. In this review, we analyze and report the current knowledge in proteomic application and strategies in the study of IBD.
溃疡性结肠炎和克罗恩病是复发性和缓解性慢性疾病。到目前为止，内镜检查是其诊断的金标准，但需要侵入性较小的诊断生物标志物。许多作者已经开发出技术来鉴别生物标志物，如在血清、血浆和细胞亚群等生物样本中的基因检测因子或蛋白质。一种蛋白质指纹图谱模式，具有患者特异性，可用于诊断炎症性肠病（IBD），并有可能预测疾病的未来模式，有助于诊断、治疗和预后，这在研究人员中越来越受到关注。如今，蛋白质组学方法可用于识别IBD中蛋白质的主要变化，但在大型临床试验中，在大量患者中识别一组生物标志物仍存在不足。在本综述中，我们分析并报告了蛋白质组学在IBD研究中的应用现状和策略。
